AKAP9 Antikörper (N-Term)

Produktnummer ABIN570727

Produktdetails anti-AKAP9 Antikörper

Target: AKAP9 (A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))

Bindungsspezifität: N-Term

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser AKAP9 Antikörper ist unkonjugiert

Applikation: ELISA

Verwendungszweck: AKAP9 / YOTIAO

Sequenz: QRKAQSDGQS PSKK

Spezifität: This antibody is expected to recognize isoforms 2 and 3 (NP_005742.4, NP_671714.1)

Kreuzreaktivität: Hund, Human

Aufreinigung: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Güteklasse: Recent

Immunogen: Peptide with sequence QRKAQSDGQSPSKK-C, from the N Terminus of the protein sequence according to NP_005742.4, NP_671714.1.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

Western Blot: Not yet tested - our routinely used western blotting protocol does not allow detection of proteins as large as the calculated size of 453 kDa according to NP_005742.4. Therefore we cannot recommend an optimal concentration and the antibody i

Peptide ELISA: antibody detection limit dilution 1:64000.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Minimize freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.

Details zu AKAP9

Target: AKAP9 (A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))

Andere Bezeichnung: AKAP9 (AKAP9 Produkte)

Synonyme: AKAP-9 antikoerper, AKAP350 antikoerper, AKAP450 antikoerper, CG-NAP antikoerper, HYPERION antikoerper, LQT11 antikoerper, MU-RMS-40.16A antikoerper, PPP1R45 antikoerper, PRKA9 antikoerper, YOTIAO antikoerper, 5730481H23Rik antikoerper, AW545847 antikoerper, C79026 antikoerper, mKIAA0803 antikoerper, Gisp antikoerper, Yotiao antikoerper, AKAP9 antikoerper, wu:fj02h02 antikoerper, prka9 antikoerper, yotiao antikoerper, akap350 antikoerper, akap450 antikoerper, hyperion antikoerper, AKAP120 antikoerper, A-kinase anchoring protein 9 antikoerper, A kinase (PRKA) anchor protein (yotiao) 9 antikoerper, A kinase (PRKA) anchor protein 9 antikoerper, A-kinase anchoring protein AKAP120 antikoerper, AKAP9 antikoerper, Akap9 antikoerper, akap9 antikoerper, CpipJ_CPIJ006715 antikoerper, CpipJ_CPIJ017436 antikoerper

Hintergrund: AKAP9, A kinase (PRKA) anchor protein (yotiao) 9, AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, MU-RMS-40.16A, PRKA9, YOTIAO, A-kinase anchor protein 9, A-kinase anchor protein, 350 kDa, A-kinase anchoring protein 450, AKAP120-like protein, AKAP9-BRAF fusi

Gen-ID: 10142

NCBI Accession: NP_005742, NP_671714

Pathways: M Phase, SARS-CoV-2 Protein Interaktom